RENVELA®

Hold Company

SANOFI

Learn More

Dosage and Administration

TABLET;ORAL

Specification

800MG

Indication

RENVELA® is used for serum phosphorus control in adults and children 6 years and older with chronic kidney disease (CKD) treated with dialysis.

Use

Instructions for Use

API

SEVELAMER CARBONATE

API Structure

We Supply

SEVELAMER CARBONATE

Note:

In-house Standard
Facility GMP
USMF/WC/FDA

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
7985418	2025/10/27

API Patent

Patent No	Expiration Date
7985418	2025/10/27

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.